OSI-906 (Linsitinib)

Catalog No.S1091

OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Price Stock Quantity  
USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

OSI-906 (Linsitinib) Chemical Structure

OSI-906 (Linsitinib) Chemical Structure
Molecular Weight: 421.49

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

IGF-1R Inhibitors with Unique Features

  • Pan IGF-1R Inhibitor

    GSK1904529A Dual IGF-1R/IR inhibitor, IC50=27 nM/25 nM.

  • Most Potent IGF-1R Inhibitor

    BMS-754807 IGF-1R, IC50=1.8 nM; InsR, IC50=1.7 nM.

  • IGF-1R Inhibitor in Clinical Trial

    BMS-754807 Phase II for Breast Cancer.

  • Newest IGF-1R Inhibitor

    PQ 401 Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Product Information

  • Compare IGF-1R Inhibitors
    Compare IGF-1R Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
Abl [1]
(Cell-free assay)

 View  More

IC50 35 nM 75 nM 75 nM >10 μM
In vitro OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
A4-FukMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRTBwMEK4NFYh|ryPMYDTRW5ITVJ?
KS-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDre4lKSzVyPUCuNFM5OzVizszNNEXUfZRUSU6JRWK=
TE-11MnPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTBwMEe4NlIh|ryPMl7sV2FPT0WU
EW-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LjOGlEPTB;MD6wPFU5PSEQvF2=MnTZV2FPT0WU
HMV-IINIfz[mlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTBwMEi4OFYh|ryPM{DCfHNCVkeHUh?=
COLO-205MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWHMfJpqUUN3ME2wMlExPDV2IN88US=>NEfUPI9USU6JRWK=
ES1NVuxVnJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXCV5lKSzVyPUCuNVA3QTZizszNNYfWeplDW0GQR1XS
GDM-1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH3RcnZKSzVyPUCuNVM3PzJizszNMlfvV2FPT0WU
ML-2M3LwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPFVHdLUUN3ME2wMlE2QDl4IN88US=>M1HKXnNCVkeHUh?=
Saos-2NYn6VZJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTBwMU[1NlYh|ryPMYnTRW5ITVJ?
NCI-H1355M2noO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXhfJp{UUN3ME2wMlE5OTN3IN88US=>NFnTO4pUSU6JRWK=
G-401Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTBwMUiyN{DPxE1?M3rKR3NCVkeHUh?=
EW-16MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLLTWM2OD1yLkG4O|c4KM7:TR?=MX7TRW5ITVJ?
EW-7M2XYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\QPHlPUUN3ME2wMlE5QDhzIN88US=>MoPtV2FPT0WU
NCI-H727NWfz[pYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTBwMUm3PVQh|ryPMVrTRW5ITVJ?
LCLC-97TM1M1nNdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;LZ4dTUUN3ME2wMlIxQTV3IN88US=>MmW1V2FPT0WU
NCI-H650NIj1cFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13z[GlEPTB;MD6yNVM5PCEQvF2=M{PnVXNCVkeHUh?=
NCI-H2122M2L1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHjb2pRUUN3ME2wMlI{Ojl7IN88US=>M1rudnNCVkeHUh?=
SK-N-DZNVTxN49{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NInJVFFKSzVyPUCuNlM3QThizszNNInoSIZUSU6JRWK=
HT-29NXS4VllZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3LlcmlEPTB;MD6yOFI1QCEQvF2=NVe0dZJ7W0GQR1XS
LB771-HNCMl3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2Ty[mlEPTB;MD6yOVkyPSEQvF2=MVLTRW5ITVJ?
HT-144NWfzWnF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zjfmlEPTB;MD6yOlE6OSEQvF2=M1TuO3NCVkeHUh?=
LAN-6MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PBT2lEPTB;MD6yOlM1QCEQvF2=NH\LfW9USU6JRWK=
EW-18MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnXPGpKSzVyPUCuNlcxODFizszNNGC4[lZUSU6JRWK=
LS-1034Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PKV2lEPTB;MD6yO|E{OiEQvF2=MWnTRW5ITVJ?
EW-11MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoW0TWM2OD1yLkK4OFMzKM7:TR?=M4nrcnNCVkeHUh?=
SNU-C1MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrlZlVKSzVyPUCuNlk{OTNizszNMX;TRW5ITVJ?
RS4-11M{XjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHr2T4FKSzVyPUCuN|M4PThizszNNYjQeXRCW0GQR1XS
ES4MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPkTWM2OD1yLkSxNFM5KM7:TR?=M2H2[XNCVkeHUh?=
COLO-320-HSRM4nWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHj3bY1KSzVyPUCuOFE{PjhizszNM{C1UHNCVkeHUh?=
NB10NIH5OJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTBwNEW0N|ch|ryPMUjTRW5ITVJ?
BFTC-905MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnZTWM2OD1yLkS2O|U5KM7:TR?=MYjTRW5ITVJ?
A375MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXhUoM3UUN3ME2wMlQ4PjF5IN88US=>NXLZTFF5W0GQR1XS
SJRH30NFntOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3S[4Y4UUN3ME2wMlUxQDJ{IN88US=>NWHleHJZW0GQR1XS
NOS-1Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTBwNUKyOlch|ryPNGHZdXhUSU6JRWK=
SIG-M5MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfSTWM2OD1yLkWzOVU4KM7:TR?=MkPFV2FPT0WU
DOKNVnjfVM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPMe2dKSzVyPUCuOVU3KM7:TR?=M2C5cHNCVkeHUh?=
NB69NGnTfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULU[5dUUUN3ME2wMlU5OjV5IN88US=>NVHOfZJ6W0GQR1XS
SK-NEP-1NXTT[pNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTBwNkCyN|Yh|ryPMWXTRW5ITVJ?
SK-MM-2MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\TTmJKSzVyPUCuOlU1QTFizszNMnXKV2FPT0WU
NCI-H358NEHQUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTpTWM2OD1yLk[3NFgzKM7:TR?=NF\DfFhUSU6JRWK=
RH-1NFHJdnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\DTlNuUUN3ME2wMlc1QDV7IN88US=>MlvSV2FPT0WU
NH-12NGnDfndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLBTWM2OD1yLke2NFQ3KM7:TR?=M1Th[XNCVkeHUh?=
TE-12MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzhd|VDUUN3ME2wMlc3PDh4IN88US=>Ml3YV2FPT0WU
COLO-668Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPZTWM2OD1yLki0OlY3KM7:TR?=MX3TRW5ITVJ?
PANC-08-13NUDx[nNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrPb5VKSzVyPUCuPFY{PzdizszNNIfaTllUSU6JRWK=
HCC2998Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfnTpRVUUN3ME2wMlg5OjZ|IN88US=>MUPTRW5ITVJ?
ABC-1NETBXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlWyTWM2OD1yLkmwN|UzKM7:TR?=MlTPV2FPT0WU
ES6MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2D5S2lEPTB;MD65NVA3PiEQvF2=M1rsXXNCVkeHUh?=
SNU-387MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{Tu[2lEPTB;MD65PVM6OyEQvF2=NYD4dpRMW0GQR1XS
CMKNVPRTI9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHP1XolKSzVyPUCuPVk6OjlizszNMo\VV2FPT0WU
SJSA-1NInLOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;YSGtKUUN3ME2xMlA{PjV|IN88US=>NHzUTZRUSU6JRWK=
SIMANXHxTld[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTFwME[4NlUh|ryPMVfTRW5ITVJ?
ES3M2S5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TUXmlEPTB;MT6xNlI6PyEQvF2=M1PqenNCVkeHUh?=
IGROV-1MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFe3UllKSzVyPUGuNVU1PDRizszNNXqxR212W0GQR1XS
MEL-JUSONWjEd4hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3i5VWlEPTB;MT6xOVc2QSEQvF2=MVjTRW5ITVJ?
T84NYjofXM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;k[IlVUUN3ME2xMlIxQTF2IN88US=>M4G4V3NCVkeHUh?=
CAL-85-1NFf3bG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrQUZJYUUN3ME2xMlI{OTN6IN88US=>NYL1XItUW0GQR1XS
RDMmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TNTWlEPTB;MT6yOlQ2PSEQvF2=MlHvV2FPT0WU
TE-8NHnTbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULvUVZHUUN3ME2xMlMyPDZ{IN88US=>NIn3VWZUSU6JRWK=
L-363MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33mR2lEPTB;MT6zOFIxQCEQvF2=MULTRW5ITVJ?
EKVXNFrUVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvuNVU3UUN3ME2xMlM1PTZ6IN88US=>NWXS[o1IW0GQR1XS
SK-MEL-3NEHEO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkD3TWM2OD1zLkS4OVU3KM7:TR?=NYm2d5lIW0GQR1XS
TGBC24TKBNXnmO|VoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTFwNUCxPVMh|ryPNFuwSpJUSU6JRWK=
NCI-H1770NGm4VXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHL3ZoZKSzVyPUGuOVEyOTNizszNMlS2V2FPT0WU
HuH-7NXi1foVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4HEXWlEPTB;MT62NFA6QCEQvF2=MYPTRW5ITVJ?
HL-60NXzQSHRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDLTWM2OD1zLk[2PVI5KM7:TR?=M3jhWnNCVkeHUh?=
TE-1NXfuXmZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnGSoRqUUN3ME2xMlcxQTR3IN88US=>M1HuPHNCVkeHUh?=
LC-2-adMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4rkUWlEPTB;MT63N|g5PyEQvF2=MlvUV2FPT0WU
LB647-SCLCMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTFwN{[1PFMh|ryPMU\TRW5ITVJ?
NCI-H2171MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\BW2lEPTB;MT63O|cyPiEQvF2=MWfTRW5ITVJ?
SK-PN-DWMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX\q[WoyUUN3ME2xMlkyOjl6IN88US=>Ml35V2FPT0WU
MC-IXCNWX3eJBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHRWGZKSzVyPUGuPVg6QCEQvF2=NUHPVXI5W0GQR1XS
LS-513NWXBPYZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3frXGlEPTB;Mj6wOVMxPSEQvF2=NEDRWGtUSU6JRWK=
EW-3NV\wTYI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13GPGlEPTB;Mj6wPVg1PCEQvF2=NV3qe|hsW0GQR1XS
OPM-2M3K3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4i1bmlEPTB;Mj6xNFIh|ryPM3PzS3NCVkeHUh?=
LP-1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHy4codKSzVyPUKuNlU5ODdizszNNFvsbHBUSU6JRWK=
LU-134-AMkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfOTWM2OD1{LkK3O{DPxE1?MofDV2FPT0WU
CP66-MELNXXrcVBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTsTWM2OD1{LkK5NFE1KM7:TR?=MW\TRW5ITVJ?
HCC1143NWLSUnhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHLE[VRKSzVyPUKuOFU{PjhizszNNHPMUlNUSU6JRWK=
LOXIMVINVPYU2NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTJwNkCyNUDPxE1?MWPTRW5ITVJ?
TE-10M2r1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfibW92UUN3ME2yMlcxQDN6IN88US=>NEfkV5RUSU6JRWK=
NCI-H1882M2jt[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1G2VWlEPTB;Mj63OVIzPyEQvF2=NInsdoJUSU6JRWK=
CHP-126M1Xacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NU[1c3VHUUN3ME2yMlc3OzF5IN88US=>NWTTNG04W0GQR1XS
NCI-H1623MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrQfXBuUUN3ME2yMlkzODJ2IN88US=>MUfTRW5ITVJ?
GB-1MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTJwOUO0NFQh|ryPMmK5V2FPT0WU
RCC10RGBM3Gyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTJwOUWyPFEh|ryPNXfsUWoyW0GQR1XS
NCI-H2141MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELxVYVKSzVyPUKuPVY5QTZizszNNW\oRWhGW0GQR1XS
GI-ME-NMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFz0Z3NKSzVyPUOuNFA2PjVizszNM3;CU3NCVkeHUh?=
NCI-H526MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX7JR|UxRTNwMESwPFUh|ryPNYC0[5FFW0GQR1XS
NCI-H747MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHZdo5KSzVyPUOuNFQ6QTJizszNNVKxOWRqW0GQR1XS
SNU-423M{HIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHMVYdmUUN3ME2zMlIxOzF|IN88US=>MWTTRW5ITVJ?
A427NWLoUZNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;kbFY1UUN3ME2zMlI2Pjl7IN88US=>NFXP[WZUSU6JRWK=
CAL-12TNEmyZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTNwNEC3NVMh|ryPMnXNV2FPT0WU
LU-99AM4XTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkfwTWM2OD1|LkS3NVA2KM7:TR?=M{XlRXNCVkeHUh?=
MS-1NXjTVJBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\qeYtyUUN3ME2zMlU{PDJ7IN88US=>NVX4cnBnW0GQR1XS
SK-LU-1MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XIT2lEPTB;Mz63OlI6PSEQvF2=NYnBell1W0GQR1XS
SW837Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjGTWM2OD1|Lke2N|M{KM7:TR?=NEHiVIlUSU6JRWK=
ES8NVfCfGg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEm1SVhKSzVyPUOuPFM5PzdizszNMUjTRW5ITVJ?
MZ2-MELNIeyTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTNwOUKwPFYh|ryPMXTTRW5ITVJ?
TGWMmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1\GTGlEPTB;ND6wNVMyOSEQvF2=MlGzV2FPT0WU
GP5dMlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\RSplKSzVyPUSuNFU{PjJizszNNXHkN2F[W0GQR1XS
BB49-HNCNF7Ee|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVHqPZVoUUN3ME20MlE2OjF|IN88US=>M2TNVXNCVkeHUh?=
NB13M160NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{i1T2lEPTB;ND6yOlg5PyEQvF2=NHG5PFNUSU6JRWK=
NTERA-S-cl-D1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILvNVhKSzVyPUSuNlg3OTVizszNNEPIdFNUSU6JRWK=
NCI-H1648NWS5Z|RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLvTWM2OD12LkK5PFE6KM7:TR?=NV74OJFQW0GQR1XS
LCLC-103HNXLSXWQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnhZ5E6UUN3ME20MlMzOTl3IN88US=>MUHTRW5ITVJ?
LS-411NM4LhVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTRwNES4PFUh|ryPM3v4c3NCVkeHUh?=
NCI-H1092Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;6TWM2OD12LkS1Olg4KM7:TR?=M4nGZXNCVkeHUh?=
PANC-10-05MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfQTWM2OD12Lk[5PFQh|ryPM2\oWXNCVkeHUh?=
DK-MGM2LVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHHTWM2OD12LkiwPVM{KM7:TR?=MoHaV2FPT0WU
OVCAR-5M33hV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTRwOEGyNlYh|ryPNInwW4ZUSU6JRWK=
CAL-39NYjrfZRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH3Wb2NKSzVyPUSuPFc3PyEQvF2=M1\tfnNCVkeHUh?=
TE-441-TMnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLu[llTUUN3ME20MlkxPTN5IN88US=>NXS4fIxLW0GQR1XS
MOLT-16MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2HKUGlEPTB;ND65OVI2OyEQvF2=Ml\xV2FPT0WU
MCF7MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{Po[mlEPTB;NT6xOFUyPyEQvF2=MV7TRW5ITVJ?
CAPAN-1Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nZeWlEPTB;NT6yOVcxPyEQvF2=NHjnOXJUSU6JRWK=
PSN1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjPbFZEUUN3ME21MlI4OjN3IN88US=>NH31enhUSU6JRWK=
NCI-H292MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XBe2lEPTB;NT6zNFA1PCEQvF2=MWrTRW5ITVJ?
CPC-NNEnVXm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTOSo5TUUN3ME21MlM6PDF7IN88US=>MUXTRW5ITVJ?
DoTc2-4510M1vMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILGW3RKSzVyPUWuOFU{PzFizszNNHrpR2tUSU6JRWK=
LB1047-RCCMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MofFTWM2OD13LkW1PVM{KM7:TR?=MnjCV2FPT0WU
MHH-ES-1NVHPRW55T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELWbG9KSzVyPUWuOVk6ODdizszNMmS2V2FPT0WU
NMC-G1NHHMWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoP3TWM2OD13LkewNlI4KM7:TR?=NVnrW4J{W0GQR1XS
SW1710MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nmZ2lEPTB;NT63OFc2OSEQvF2=MkPxV2FPT0WU
YAPCMnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTVwN{[yNFEh|ryPMmriV2FPT0WU
22RV1MlvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7oc2VKSzVyPUWuPFAxOTlizszNM4DWV3NCVkeHUh?=
COLO-679MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTHTWM2OD13Lki4PVQ5KM7:TR?=NGf5cG9USU6JRWK=
TCCSUPNYnhe3NmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUjJR|UxRTVwOUOyOVkh|ryPMWjTRW5ITVJ?
C2BBe1MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfa[4xnUUN3ME21Mlk{QTdizszNNXXrcoxWW0GQR1XS
TE-15M1joOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTZwME[2NFUh|ryPNYnZTZB5W0GQR1XS
SCLC-21HNU\NVlhXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYS4Zot3UUN3ME22MlExQDR|IN88US=>M{nyZ3NCVkeHUh?=
EoL-1-cellM2L4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVzJR|UxRTZwMU[1OlMh|ryPNWnEfXZEW0GQR1XS
NKM-1M1Hsb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{SxXmlEPTB;Nj6xOlcyKM7:TR?=MVTTRW5ITVJ?
NCI-H1304MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\GNpFKSzVyPU[uNlc1OjhizszNMkDMV2FPT0WU
NB6MleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3peFl2UUN3ME22MlI6PjJ{IN88US=>NH\MWmRUSU6JRWK=
NALM-6M2\GR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\MPHhlUUN3ME22MlM{OjNizszNMY\TRW5ITVJ?
NCI-H522MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTjOop3UUN3ME22MlM{OzB4IN88US=>NUj6[3FnW0GQR1XS
MV-4-11NHmxSVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTZwM{ewO|kh|ryPMkLBV2FPT0WU
LB2241-RCCNI\tSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVGxWXlDUUN3ME22MlM5PjZ5IN88US=>NYP0d3ZZW0GQR1XS
NCI-H1417NHrhTWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnfUTWM2OD14LkSwPFQ4KM7:TR?=M4jpV3NCVkeHUh?=
HT-1197MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTZwNUexNlIh|ryPMVHTRW5ITVJ?
P30-OHKMY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTBSWlDUUN3ME22MlYzPzdizszNMWrTRW5ITVJ?
ALL-PONVj4U5JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrsXHkzUUN3ME22MlcyQTF4IN88US=>MXHTRW5ITVJ?
OVCAR-4MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTZwN{W0NFUh|ryPNImwZnBUSU6JRWK=
HCC2157M2\4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LEPWlEPTB;Nj63O|Q4PSEQvF2=M3\vVnNCVkeHUh?=
NCI-H838MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnSxTWM2OD14Lkm2OFkh|ryPM{j0WnNCVkeHUh?=
NCI-H1299M1vZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfGdm44UUN3ME22Mlk4ODlizszNM4WzdXNCVkeHUh?=
SW954NIfVTHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTdwMkCwOlgh|ryPNV7vdnhFW0GQR1XS
NCI-H441MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjJOFg5UUN3ME23MlM1ODZ3IN88US=>MUHTRW5ITVJ?
SK-MEL-2NFLxc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTdwNEizO|Mh|ryPNFe5RodUSU6JRWK=
KARPAS-45NXn2ZoxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHYR5ZYUUN3ME23MlY2QTJ7IN88US=>MWrTRW5ITVJ?
CAL-54MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDtPHF6UUN3ME23MlgzQTd5IN88US=>NIDSO|NUSU6JRWK=
KYSE-180MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXOUJNKSzVyPUeuPFg6PDFizszNMkLPV2FPT0WU
NCI-H187NUnuTopZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1O3S2lEPTB;Nz65OVk1PyEQvF2=M{jo[nNCVkeHUh?=
RT-112MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLmTWM2OD16LkC5Olc4KM7:TR?=NWnDUm15W0GQR1XS
NCI-H1437NET5bppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRThwMEm3PVUh|ryPMVPTRW5ITVJ?
SNU-449NYPPc4M2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LX[WlEPTB;OD6yPFI4OiEQvF2=MYHTRW5ITVJ?
HCC1187NFz1cmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRThwMkmzPVEh|ryPNHzjfopUSU6JRWK=
NCI-H2030NHexOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Moq2TWM2OD16LkO3O|E1KM7:TR?=NXXzVI8xW0GQR1XS
HuO-3N1M176bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\veWlEPTB;OD6zO|g1PCEQvF2=MYjTRW5ITVJ?
COLO-792NU\5fpBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWf5UFR6UUN3ME24MlQyPTJ5IN88US=>NGXyRlFUSU6JRWK=
MIA-PaCa-2NUC4N5VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRThwOEW1NFgh|ryPNIrteIVUSU6JRWK=
SK-N-FIMlHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUCwbYwyUUN3ME25MlA1OjVizszNMYHTRW5ITVJ?
MMAC-SFM1H2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWLnWFZZUUN3ME25MlA6PzVzIN88US=>MVnTRW5ITVJ?
NCI-H28MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mny0TWM2OD17LkGwOFY6KM7:TR?=NVm4e29NW0GQR1XS
ETK-1NYPEO4pkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TBNWlEPTB;OT6yPVk4PCEQvF2=M3;lOHNCVkeHUh?=
NCI-H1993NHXDeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXyxVHk{UUN3ME25MlQ1OjZzIN88US=>MUXTRW5ITVJ?
no-11MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFruXYxKSzVyPUmuOFcyOiEQvF2=M4fRd3NCVkeHUh?=
ChaGo-K-1NXvM[|FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2PYSmlEPTB;OT61NVU5OyEQvF2=MW\TRW5ITVJ?
NCCITMln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7QTWM2OD17LkWzNVY6KM7:TR?=NFfBRZNUSU6JRWK=
SASM1vK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTFyLkK0PEDPxE1?MYfTRW5ITVJ?
A673M1H1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlPiTWM2OD1zMD6zO|A1KM7:TR?=MX;TRW5ITVJ?
NCI-H1522M4Dxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTFyLkO3NFch|ryPM3\GVHNCVkeHUh?=
NCI-H810M2D3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfodVNmUUN3ME2xNE4{QTB5IN88US=>M{TWW3NCVkeHUh?=
IST-MES1M1ftN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Moj2TWM2OD1zMD60OVY1KM7:TR?=MmC4V2FPT0WU
GR-STMl\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF[3NmdKSzVyPUGwMlUxOjRizszNNX;xTIx{W0GQR1XS
SUP-T1Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mkm1TWM2OD1zMD63N|E4KM7:TR?=M333ZnNCVkeHUh?=
NB5MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjRWVQ2UUN3ME2xNE46ODJ{IN88US=>NIjPdmhUSU6JRWK=
MZ1-PCNUj1WYQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PoSGlEPTB;MUCuPVU4OSEQvF2=MonKV2FPT0WU
SK-CO-1MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\5TWM2OD1zMD65PVMyKM7:TR?=Mk\nV2FPT0WU
Capan-2M2raUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHVTWM2OD1zMT6zNVk5KM7:TR?=NFGyWIJUSU6JRWK=
697MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIf1O45KSzVyPUGxMlY4PTdizszNM165VHNCVkeHUh?=
REHM2jiTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M36xZWlEPTB;MUGuO|Q2OSEQvF2=MWDTRW5ITVJ?
GI-1NYC4TWY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjjTWM2OD1zMT64OlE2KM7:TR?=MVTTRW5ITVJ?
BB65-RCCM2rNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTK[GNHUUN3ME2xNk4xQTF4IN88US=>MkG3V2FPT0WU
NCI-H1651NU\BXJpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnQdJlJUUN3ME2xNk4zPDd6IN88US=>MYjTRW5ITVJ?
NCI-H1618M1[3SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPxXllCUUN3ME2xNk4{QTd4IN88US=>NHvoSJdUSU6JRWK=
NCI-H2081NFr2N2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2[3NmlEPTB;MUKuOlE1OSEQvF2=MnTOV2FPT0WU
GCIYNWXJOXY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjDNYlKSzVyPUGyMlczOTNizszNNVTWSoRSW0GQR1XS
NYNX;HcpNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2L0OWlEPTB;MUOuNFY1OyEQvF2=MWnTRW5ITVJ?
PANC-03-27NVXXNnBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDVUpJKSzVyPUGzMlA5ODdizszNMmCzV2FPT0WU
BHYMo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XYN2lEPTB;MUOuNlEzOSEQvF2=NV\jeJZUW0GQR1XS
SK-OV-3MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzTTWM2OD1zMz6zO|Y{KM7:TR?=NEO5NHpUSU6JRWK=
5637MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;XS5EzUUN3ME2xN{44PzV7IN88US=>M2nLUnNCVkeHUh?=
LC-1FMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTF2LkCzOVYh|ryPMoj6V2FPT0WU
SNB75NUPFTm97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\scGV1UUN3ME2xOE4xOzh|IN88US=>MlPMV2FPT0WU
CHP-212NXj4[2FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTF2LkC0OlQh|ryPMlTUV2FPT0WU
HT-1376NUfzbHhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTQTWM2OD1zND6xNVI3KM7:TR?=MnHwV2FPT0WU
MONO-MAC-6NYPsN4lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTF2LkG1NFIh|ryPMlj3V2FPT0WU
CA46M3jQZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3TpbmlEPTB;MUSuNVgzPyEQvF2=NEjuZZNUSU6JRWK=
SCC-15MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIP6[odKSzVyPUG0MlU2QDNizszNMUDTRW5ITVJ?
ATN-1M2PNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLFPVBWUUN3ME2xOE43PjJ5IN88US=>NXy0TGJmW0GQR1XS
NCI-H2405NXnOZnpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnnTTWM2OD1zND64NVU4KM7:TR?=MnGyV2FPT0WU
NCI-H716NH7sXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPWZpFpUUN3ME2xOE45PDl|IN88US=>M3uwb3NCVkeHUh?=
SW620NFK3O|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjCT25KSzVyPUG0MlkxOTRizszNNYHpPYd2W0GQR1XS
NCI-H226NEKzclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjFU4tIUUN3ME2xOE46ODh3IN88US=>M3ruenNCVkeHUh?=
SW962MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fzPWlEPTB;MUSuPVQ{OiEQvF2=NWT1XIVnW0GQR1XS
KYSE-150NH7zbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGj3VY5KSzVyPUG0Mlk2PSEQvF2=M4PH[3NCVkeHUh?=
OCUB-MMoXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTF2Lkm4PFMh|ryPMlLjV2FPT0WU
ES7NVvRfWJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTF3LkC5PFQh|ryPMWLTRW5ITVJ?
SW1463MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoGwTWM2OD1zNT60NlI{KM7:TR?=MkDpV2FPT0WU
CAKI-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTTbnNKSzVyPUG1MlU{PDZizszNNHzQXJFUSU6JRWK=
MKN28MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUWzN3dqUUN3ME2xOU42PDd7IN88US=>NXf0NFdTW0GQR1XS
SW13M4CyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDY[lM6UUN3ME2xOU43OThizszNM4PSc3NCVkeHUh?=
A3-KAWNUXlOnd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTF3Lkm2PVch|ryPMmPIV2FPT0WU
LU-65MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn35TWM2OD1zNT65O|Y5KM7:TR?=NV;HNY4yW0GQR1XS
Calu-1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTF4LkCzOlgh|ryPNUeyZnVbW0GQR1XS
ST486NF\2cWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmn6TWM2OD1zNj6wOFMyKM7:TR?=NVXySXY4W0GQR1XS
BB30-HNCMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LVNmlEPTB;MU[uNVI1PiEQvF2=MVHTRW5ITVJ?
EGI-1MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXkTWM2OD1zNj60OFYh|ryPM1;VZ3NCVkeHUh?=
SH-4MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYG4dmttUUN3ME2xOk41PzNzIN88US=>MU\TRW5ITVJ?
MN-60MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmj1TWM2OD1zNz6yNlk4KM7:TR?=NY\abYJEW0GQR1XS
MPP-89MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXy2NmNZUUN3ME2xO{4zPDV7IN88US=>MnP3V2FPT0WU
A2780M3j5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jsV2lEPTB;MUeuOFE{QSEQvF2=MoDaV2FPT0WU
DaoyNXP5c4g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfpOpFKSzVyPUG3MlQ3QTVizszNMYrTRW5ITVJ?
NCI-H2126NXPubFY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTF5LkS3O|Eh|ryPNH3Wbm1USU6JRWK=
NCI-H1563NUi3XGJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LMOWlEPTB;MUeuOFkyPyEQvF2=NGjFW4tUSU6JRWK=
8-MG-BANFLZNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmntTWM2OD1zNz62OlQ5KM7:TR?=M3Ppe3NCVkeHUh?=
786-0NYGyelh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jzVGlEPTB;MUeuPFM2OyEQvF2=MXjTRW5ITVJ?
AM-38NXT3UoE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2O4PWlEPTB;MUeuPVMxPiEQvF2=M3LlT3NCVkeHUh?=
COLO-824M336N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTF6LkS0N|Yh|ryPNEjpUI1USU6JRWK=
SK-MEL-30MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\CfVRKSzVyPUG4MlUxQDJizszNMmL2V2FPT0WU
CESSMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PtbGlEPTB;MUiuO|YxQSEQvF2=M33rUnNCVkeHUh?=
BL-70NEHudHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXlNpRKSzVyPUG4MlgyPTZizszNMYTTRW5ITVJ?
NCI-H2170MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;L[|dUUUN3ME2xPE46OTd7IN88US=>MUDTRW5ITVJ?
HT-3MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPRTWM2OD1zOD65PFMh|ryPM2HIcHNCVkeHUh?=
BOKUMmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3B[W81UUN3ME2xPU4xOzhzIN88US=>NYjwbItlW0GQR1XS
HPAF-IINFTjdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTF7LkOwNVUh|ryPNVzBd3lIW0GQR1XS
KGNNH\rfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTF7LkS3OlUh|ryPMne2V2FPT0WU
MC-CARNV\tN2lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmT2TWM2OD1zOT62N|E{KM7:TR?=NXHIe4RMW0GQR1XS
BHT-101MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInj[YxKSzVyPUG5Mlc4PyEQvF2=M1f1VXNCVkeHUh?=
SW1783NHjT[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLsTWM2OD1zOT63PFA3KM7:TR?=M3TqVHNCVkeHUh?=
KP-N-YNNGTMcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTIToFKSzVyPUKwMlAzPjJizszNNXu2elFwW0GQR1XS
LU-165MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\vR4NKSzVyPUKwMlU2PzFizszNMXzTRW5ITVJ?
GOTOMmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIOxVIFKSzVyPUKwMlY1PTFizszNMX3TRW5ITVJ?
EFM-19MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;nUWlEPTB;MkGuNFcyPiEQvF2=NFnoeXBUSU6JRWK=
CTV-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm[xTWM2OD1{MT6xNFU1KM7:TR?=M3u3TnNCVkeHUh?=
HELNXvuNGsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{H1fGlEPTB;MkGuOFIyPiEQvF2=MkXzV2FPT0WU
SNU-C2BM2e2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTJzLkSyOkDPxE1?NFvHTHVUSU6JRWK=
ECC4Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYrJR|UxRTJzLkewO{DPxE1?NFvMSoRUSU6JRWK=
NEC8MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXWxU5pYUUN3ME2yNU45OzZ6IN88US=>NIfqZXhUSU6JRWK=
KMOE-2MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjDS3EzUUN3ME2yNU45QTJzIN88US=>MmPyV2FPT0WU
NCI-H524NITGXHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3vVoljUUN3ME2yNk4xQDB6IN88US=>NGDkd|lUSU6JRWK=
WSU-NHLNVfMO5ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTJ{LkG1O|ch|ryPM1m4eHNCVkeHUh?=
SF126M1LuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1[yOGlEPTB;MkKuNlQ3QSEQvF2=MYPTRW5ITVJ?
HOP-92M4n4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTJ{LkOxOlch|ryPMkKyV2FPT0WU
CTB-1MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7NZWNSUUN3ME2yNk41Pjd5IN88US=>NIXvNZNUSU6JRWK=
KYSE-270MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Moe4TWM2OD1{Mj65N|U4KM7:TR?=MoLBV2FPT0WU
SK-MEL-24NVfiXIJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fOUGlEPTB;MkOuNVg4KM7:TR?=M1vMfnNCVkeHUh?=
Calu-3MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\NOFJtUUN3ME2yN{4zOTJ6IN88US=>NUfLb4pHW0GQR1XS
GAMGMmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHOxU5JKSzVyPUKzMlI{PjdizszNMX7TRW5ITVJ?
SW1573Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILjVldKSzVyPUKzMlc1OTVizszNNYHQd5FJW0GQR1XS
MHH-NB-11NXjPO4U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrqUnc6UUN3ME2yOE4xOTl2IN88US=>NFHpXlJUSU6JRWK=
TK10M4DsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF21NoJKSzVyPUK0MlUxOTNizszNMVLTRW5ITVJ?
LB373-MEL-DNGC4ZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7WVHdwUUN3ME2yOE43ODZ2IN88US=>MU\TRW5ITVJ?
KALS-1NUXKO3ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXBOYtKSzVyPUK0Mlc{OjdizszNM2\Q[3NCVkeHUh?=
HUTU-80NEK0ZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1r6OmlEPTB;MkWuPFA{OiEQvF2=Mkm0V2FPT0WU
HuP-T3NYrOclhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjJTWM2OD1{Nj6xOlc1KM7:TR?=MlfKV2FPT0WU
OE19NWXWdIVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;XbnRyUUN3ME2yOk4zOTV|IN88US=>M1y4R3NCVkeHUh?=
J82NVf1XHdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTJ4LkK0O|Eh|ryPNUjHUGk5W0GQR1XS
DU-4475NIXtToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLpdGJKSzVyPUK2MlM5OTlizszNMkDZV2FPT0WU
DMS-53MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mki3TWM2OD1{Nj61NVM5KM7:TR?=NIr3e3JUSU6JRWK=
COLO-741Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVL2cXkzUUN3ME2yOk45OzR2IN88US=>NFHXS|JUSU6JRWK=
SW48NFzHR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTJ4Lki4NkDPxE1?M3PwTHNCVkeHUh?=
IGR-1NY[4[2piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2\od2lEPTB;Mk[uPVM{PCEQvF2=M2\qSXNCVkeHUh?=
639-VNGHxfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfmXHFkUUN3ME2yO{4xOjR3IN88US=>NGnyUnNUSU6JRWK=
LK-2NWHrZ4tuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fxTmlEPTB;MkeuOFE1OSEQvF2=MX7TRW5ITVJ?
NCI-H2347MljpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rKTGlEPTB;MkeuPVY6QSEQvF2=MlPHV2FPT0WU
NCI-H2228MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1m2eGlEPTB;MkiuNFkxPSEQvF2=NG\jZo9USU6JRWK=
LS-123NFLKZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2n1UWlEPTB;MkiuNVI3OiEQvF2=MXHTRW5ITVJ?
U031M4C3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTJ6LkK1NkDPxE1?M4HhUnNCVkeHUh?=
NCI-H1792NGj1WlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzISWZJUUN3ME2yPE41PzJzIN88US=>NXHPS45YW0GQR1XS
NCI-H2087NX3tOWoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTJ6Lke1OVIh|ryPM{DBfnNCVkeHUh?=
NCI-H2342MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3Z[pZKSzVyPUK5MlUzODhizszNMULTRW5ITVJ?
SW626M3\2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHqTWM2OD1{OT63OVYh|ryPNULSTppjW0GQR1XS
LB2518-MELNV;LOHF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nMUGlEPTB;MkmuPFE2KM7:TR?=NWO0R5MyW0GQR1XS
RXF393M4r0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3lWldKSzVyPUOwMlA6PTJizszNM4PmXHNCVkeHUh?=
LC4-1MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LMZWlEPTB;M{CuN|A6OiEQvF2=Mli2V2FPT0WU
NCI-H1694NX\GOVJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTNyLk[2NlQh|ryPNX\RRVFzW0GQR1XS
K5MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVTRWoI6UUN3ME2zNE46PzB{IN88US=>NX7DOnY5W0GQR1XS
HDLM-2MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvoe3lKSzVyPUOwMlk4OjVizszNMWPTRW5ITVJ?
BCPAPM2Lnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjGW2RqUUN3ME2zNU45Ozd7IN88US=>MnfrV2FPT0WU
BC-3Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2LYS2lEPTB;M{KuNVQxOyEQvF2=Ml[2V2FPT0WU
LB996-RCCMm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLETWM2OD1|Mj6yN|U5KM7:TR?=NXPZWJRHW0GQR1XS
NCI-H2009M2PaU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4L4emlEPTB;M{KuOFk5OSEQvF2=NE\ib5hUSU6JRWK=
HTC-C3NE\STWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\GNVlKSzVyPUOzMlc2OTlizszNMVrTRW5ITVJ?
LAMA-84NV;aOItXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzETWM2OD1|ND60OFA4KM7:TR?=M2PX[XNCVkeHUh?=
CCRF-CEMM3LJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn:3TWM2OD1|ND61O|E2KM7:TR?=MonxV2FPT0WU
AN3-CAMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7QTWM2OD1|NT6wOVY5KM7:TR?=NXvUR4hzW0GQR1XS
NCI-H1734NU\oR4I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEL2XFFKSzVyPUO1MlI2PjFizszNMUDTRW5ITVJ?
Ca-SkiNUnMNmRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV76[XhEUUN3ME2zOU41OTBzIN88US=>MoDlV2FPT0WU
U-266M1;yfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XqUWlEPTB;M{WuOlEyPCEQvF2=MmG4V2FPT0WU
SBC-5MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHUS4FrUUN3ME2zOU44PzhzIN88US=>MkDDV2FPT0WU
GT3TKBMnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTN5LkGxOUDPxE1?M3;HRnNCVkeHUh?=
MDA-MB-175-VIINHn4WmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4Dh[mlEPTB;M{euNlI1QCEQvF2=NX24bnNKW0GQR1XS
PFSK-1NWXX[FNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTN5LkK0N|Uh|ryPNGHhWYtUSU6JRWK=
IMR-5M1zqbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7sNnpKSzVyPUO3MlI1QDdizszNM4e1OXNCVkeHUh?=
DaudiMn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3f3eWlEPTB;M{euN|U6PyEQvF2=M4LvdnNCVkeHUh?=
A498MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTN5LkeyNVgh|ryPNFr1UHZUSU6JRWK=
SCC-4NIH5OnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnkXI9KSzVyPUO3Mlc5PDNizszNMXjTRW5ITVJ?
COLO-680NMkDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13DUmlEPTB;M{iuNlg5PSEQvF2=NXLoemhzW0GQR1XS
SK-MES-1NVfrN4dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTGTWM2OD1|OD6zNlE2KM7:TR?=NYPLWI5RW0GQR1XS
SRM33ZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITWN5ZKSzVyPUO4MlU1QTVizszNM3;3enNCVkeHUh?=
LNCaP-Clone-FGCM37vU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7MO2E2UUN3ME2zPE42PjN5IN88US=>Mof6V2FPT0WU
SK-HEP-1M{fFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTCTWM2OD1|OD63PFIzKM7:TR?=MY\TRW5ITVJ?
BPH-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXCTWM2OD1|OD64N|I6KM7:TR?=MVXTRW5ITVJ?
NCI-H1755MnO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnywTWM2OD1|OT61PFE4KM7:TR?=NWG2fW02W0GQR1XS
LXF-289MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoTmTWM2OD1|OT64NFg1KM7:TR?=M2noZXNCVkeHUh?=
SW1088NETMXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;NTWM2OD12MD6yNVA4KM7:TR?=MYTTRW5ITVJ?
MOLT-4NFnkPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3f4UWlEPTB;NECuNlkxOSEQvF2=M2jmcHNCVkeHUh?=
AsPC-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkX3TWM2OD12MD60OVg{KM7:TR?=NXSyN|dxW0GQR1XS
HOP-62M{TYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M16yTGlEPTB;NECuOlU3QCEQvF2=Mo\PV2FPT0WU
A172NXvIR2Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrhSo1KSzVyPUSwMlg2OTFizszNMmW2V2FPT0WU
SN12CM2rVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX3kbVZFUUN3ME20NE46Ozh3IN88US=>NYe3VGxPW0GQR1XS
MDA-MB-231MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYK1XWd7UUN3ME20NE46QDl6IN88US=>MoDHV2FPT0WU
RPMI-2650M3nQT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTRzLkG1PVMh|ryPMX7TRW5ITVJ?
KYSE-140NIfjRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIq1bHVKSzVyPUSxMlgyOjNizszNNVnqT5FvW0GQR1XS
KINGS-1NFnx[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDwTWM2OD12Mj60Olk4KM7:TR?=MUHTRW5ITVJ?
HSC-3MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoT5TWM2OD12Mj62OlYyKM7:TR?=MYPTRW5ITVJ?
PC-14MmX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWDHdnJbUUN3ME20N{4yQDh{IN88US=>M1;KXHNCVkeHUh?=
COR-L105NFG1bWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjadYJKSzVyPUSzMlY2ODJizszNNWm0OWh6W0GQR1XS
BE-13MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHXHdlBKSzVyPUS0MlI{PzFizszNM1\oRnNCVkeHUh?=
NCI-H661MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVra[pM2UUN3ME20OE4zQTV6IN88US=>MXHTRW5ITVJ?
IST-MEL1NXS5bGlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTR2LkO1PVkh|ryPMoLMV2FPT0WU
HCC1806NEHZR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHT6fFlKSzVyPUS0MlU5PzNizszNMVnTRW5ITVJ?
COLO-800MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTR2Lki0OVMh|ryPNIjDVIFUSU6JRWK=
IST-SL2MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVG2dZlLUUN3ME20OU4yOjR5IN88US=>NXXrRnoyW0GQR1XS
8305CM1HhVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rzcmlEPTB;NEWuN|A6KM7:TR?=NFXXdlRUSU6JRWK=
UACC-62MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3qwR2lEPTB;NE[uNlg4PSEQvF2=NWL0e4J2W0GQR1XS
COR-L23MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jiUGlEPTB;NEeuNVk6KM7:TR?=MUPTRW5ITVJ?
EFE-184MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTR5LkO4PEDPxE1?MYfTRW5ITVJ?
DMS-114NXnsRXhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTR5LkSxOFkh|ryPNVfZN41TW0GQR1XS
KYSE-520MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrkcHJkUUN3ME20PE42OzF3IN88US=>MWPTRW5ITVJ?
SNG-MNVHRXWNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfPfmdoUUN3ME20PU41OzRizszNMX;TRW5ITVJ?
A2058MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPzT3NKSzVyPUS5MlQ5QDVizszNMlixV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]
Features

Protocol(Only for Reference)

Kinase Assay: [1]

Protein kinase biochemical assays Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.

Cell Assay: [1]

Cell lines MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
Concentrations 0.02-0.8 μM
Incubation Time 3 days
Method For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.

Animal Study: [1]

Animal Models IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
Formulation 25 mM tartaric acid
Dosages 25 mg / kg and 75 mg / kg
Administration Orally administrated at once-daily oral dose for 14 days

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Mulvihill MJ, et al. Future Med Chem, 2009, 1(6), 1153-1171.

[2] McKinley ET, et al. Clin Cancer Res, 2011, 17(10), 3332-3340.

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02057380 Active, not recruiting Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research a  ...more University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2

view more

Chemical Information

Download OSI-906 (Linsitinib) SDF
Molecular Weight (MW) 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 84 mg/mL (199.29 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG 400+0.5% Tween 80+5% Propylene glycol 30mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (1s,3s)-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related IGF-1R Products

  • Picropodophyllin (PPP)

    Picropodophyllin (PPP) is a selective IGF-1R inhibitor with IC50 of 1 nM. Phase 1/2.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • BMS-536924

    BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

  • NVP-AEW541

    NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.

  • NVP-ADW742

    NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.

  • GSK1904529A

    GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.

  • BMS-754807

    BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

    Features:Muti-inhibitor of the IGR-1R/IR family.

  • AG-1024

    AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).

  • PQ 401

    PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Recently Viewed Items

Tags: buy OSI-906 (Linsitinib) | OSI-906 (Linsitinib) supplier | purchase OSI-906 (Linsitinib) | OSI-906 (Linsitinib) cost | OSI-906 (Linsitinib) manufacturer | order OSI-906 (Linsitinib) | OSI-906 (Linsitinib) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us